Resveratrol-4-O-D-(2'-galloyl)-glucopyranoside isolated from Polygonum cuspidatum exhibits anti-hepatocellular carcinoma viability by inducing apoptosis via the JNK and ERK pathway.
Resveratrol-4-O-D-(2'-galloyl)-glucopyranoside (RESG) is one of the active compounds isolated from Polygonum cuspidatum. The purpose of our present study was to investigate the anti-hepatocellular carcinoma effect of RESG in vitro and in vivo, and the possible mechanisms in vitro. In vitro, our results showed that RESG could significantly inhibit the human hepatocellular carcinoma viability in the MTT assay, in a dose- and time-dependent manner. Furthermore, our results demonstrated that RESG could induce SMMC-7721 cell apoptosis and activate caspases 3 and caspases 9 by using Annexin V-FITC staining and western blot, respectively. In vivo, RESG also showed efficacy in SMMC-7721 xenograft model in nude mice, and further molecule mechanisms were investigated in vitro. The results showed that RESG up-regulated the p-JNK expressions, whereas it down-regulated the p-ERK expressions. Above results demonstrated that RESG is a potential therapeutic agent for hepatocellular carcinoma via JNK and ERK pathway to induce apoptosis. Our finding provided a basis for further development of RESG as an anticancer agent.
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. xieqctmmu@126.com.
Qichao
Q
Xie
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. yangypxqh@126.com.
Yupeng
Y
Yang
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. wangzyxqh@126.com.
Zhiyi
Z
Wang
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. chenfanglin2012@163.com.
Fanglin
F
Chen
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. amayzhang@yeah.net.
Anmei
A
Zhang
Department of Oncology, the Second Affiliated Hospital, Third Military Medical University, Chongqing 400037, China. liu_xqh@163.com.
Chengcheng
C
Liu
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D045468:Fallopia japonica / Q000737:chemistry; D020719:Glucuronides / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020935:MAP Kinase Signaling System / Q000187:drug effects; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D051379:Mice; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*; D013267:Stilbenes / Q000737:chemistry / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
D020719:Glucuronides; D010936:Plant Extracts; D013267:Stilbenes; C499731:resveratrol-4'-O-glucuronide